Nuvo Pharmaceuticals Announces Appointment of Rob Harris as Executive Chairman

MISSISSAUGA, ON, Jan. 3, 2019 /PRNewswire/ – Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX : NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Rob Harris as its Executive Chairman. Mr. Harris joined Nuvo’s board of directors in May 2017 and was previously the co-founder and Chief Executive Officer of Tribute Pharmaceuticals Inc. (Tribute), formerly a Toronto Stock Exchange listed company. Tribute was purchased in 2016 by Aralez Pharmaceuticals Inc., renamed Aralez Canada Inc. and then purchased by Nuvo in a transaction that was completed December 31, 2018. Mr. Harris assumes the Executive Chairman role from John London who will become the Company’s non-executive Vice-Chairman. Both Mr. Harris and Mr. London will continue as members of the Nuvo board.

“We are pleased that Rob was available and willing to assume this important leadership role at Nuvo,” said John London, Nuvo’s Vice-Chairman. “As the co-founder of Tribute, Rob is intimately familiar with the products, personnel and infrastructure that Nuvo has just acquired. His over 35 years of pharmaceutical experience will prove invaluable as we embark on the process of effectively integrating and growing our newly acquired and existing businesses.”

“The Aralez transaction is truly transformational for Nuvo,” said Rob Harris and “I welcome the opportunity to work more closely with Jesse Ledger, our CEO and the entire Nuvo team who worked tirelessly in 2018 to complete this transaction. Similarly, the Aralez Canada team has achieved significant growth since the sale of Tribute in 2016 and the integration of both teams will lead to a much stronger, combined business.”

Mr. Harris has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management. Mr. Harris most recently served as President and CEO of Tribute Pharmaceuticals. Prior to co-founding Tribute Pharmaceuticals, Rob was the President & CEO of Legacy Pharmaceuticals Inc. Mr. Harris also has previous experience at Biovail Corporation where as Vice President of Business Development, he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Prior to Biovail, Mr. Harris worked in various senior commercial management positions during his twenty-year tenure at Wyeth (Ayerst) including its animal health group and has been involved in numerous product launches during his career.

About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Nuvo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the U.S. Food and Drug Administration (FDA), Health Canada and E.U. approved manufacturing facility is located in Varennes, Qu├ębec, Canada. For additional information, please visit www.nuvopharmaceuticals.com.